Chimeric Therapeutics Past Earnings Performance
Past criteria checks 0/6
Chimeric Therapeutics's earnings have been declining at an average annual rate of -20.5%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 121.5% per year.
Key information
-20.5%
Earnings growth rate
46.6%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 121.5% |
| Return on equity | -84.6% |
| Net Margin | -94.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Chimeric Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 12 | -12 | 12 | 12 |
| 30 Sep 23 | 8 | -19 | 14 | 13 |
| 30 Jun 23 | 5 | -26 | 15 | 14 |
| 31 Mar 23 | 5 | -22 | 14 | 12 |
| 31 Dec 22 | 6 | -18 | 13 | 9 |
| 30 Sep 22 | 4 | -17 | 12 | 8 |
| 30 Jun 22 | 3 | -16 | 11 | 6 |
| 31 Mar 22 | 1 | -19 | 13 | 6 |
| 31 Dec 21 | 0 | -21 | 14 | 6 |
| 30 Sep 21 | 0 | -18 | 13 | 5 |
| 30 Jun 21 | 0 | -15 | 11 | 4 |
Quality Earnings: CHM is currently unprofitable.
Growing Profit Margin: CHM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CHM is unprofitable, and losses have increased over the past 5 years at a rate of 20.5% per year.
Accelerating Growth: Unable to compare CHM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: CHM has a negative Return on Equity (-84.58%), as it is currently unprofitable.